title: [Neuroblastoma].
abstract: Neuroblastoma is an embryonal tumour of childhood. Primary tumours are localized retroperitoneally or abdominally. Neuroblastoma produce catecholamine metabolites which are used as tumour markers. MIBG scintigraphy in addition to ultrasound and nuclear magnetic resonance tomography allow specific imaging of the tumour tissue. In young patients, spontaneous remissions are not uncommon, whereas the outcome in older children is poor despite intensive treatment. Therefore, the treatment of neuroblastoma must be risk adapted. The 5 year overall survival rates in the German NB97 trial were 96+/-1% in the observation group, 89+/-3% in the median risk group, and 50+/-3% in the high risk group.
authors.affiliation: Pädiatrische Onkologie und Hämatologie, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universität Köln. thorsten.simon@uk-koeln.de
authors.forename: T
authors.initials: T
authors.lastname: Simon
mesh_terms: D000008:Abdominal Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009447:Neuroblastoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016019:Survival Analysis